• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 6/24/24: Probiotics Could Benefit Oral Health, Is AI Right More Often Than Humans? & more


The latest news for pharma industry insiders.

Navigating Market Access Hurdles

Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.

Probiotics Could Also Benefit Oral Health

Recent research findings published in Pharmaceuticals suggest that probiotic microorganisms, typically used for gut health, could also benefit dental health. According to the literature review, probiotics are associated with reduced cariogenic pathogens and protection against periodontal diseases, although the exact mechanism is unknown.

Operational Oversight in Clinical Research: Integrations and Insights

Learn how IQVIA’s CDAS technology and services can provide an efficient path to consolidating and harmonizing data across any provider source, ensuring high quality oversight of outsourced clinical trial activities.

If AI Is More Often Right Than Humans, Which Should We Trust? The Readers Weigh In

New advancements may mean that we turn more decision-making over to machines. Is that a good thing?

Epilepsy Drugs Market, Size, Global Research 2024-2030

The "Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global epilepsy drugs market is expected to approach approximately US$ 10.28 billion by 2030 from US$ 7.62 Billion in 2023. Between 2024 and 2030, the global epilepsy drugs market is predicted to develop at a compound annual growth rate (CAGR) of 4.37%.

81qd on LinkedIn

How AI Can Improve Engagement with Healthcare Professionals (HCPs)?

Successful AI adoption, specifically in HCP marketing, will require a thoughtful, customer-centric approach to avoid aggravating the promotional fatigue and dissatisfaction fostered by drugmakers' dash toward digital since COVID-19. This Pharmaceutical Executive article provides an overview of some key areas for AI integration that can help improve the HCP customer experience and Joe DeLuca highlights 81qd's role in this space as an advanced analytics firm that combines real-world data, artificial intelligence, human analysis, and deep healthcare domain knowledge to identify high-impact segments.


#HCPengagement #pharma #artificialintelligence #81qd

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs